Known targets — ChEMBL curated mechanism
ABCC9ABL1ACEACHEACVR1ADORA1ADORA2AADORA2BADORA3ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALOX5ATP4AATP4BBCRBTKCACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNB1CHRNDCHRNECHRNGCRBNCUL4ACXCR1CXCR2DDB1DDCDHFRDPP4DRD2DRD3DRD4EGFRERBB2ERBB4ESR1ESR2FDPSFKBP1AFLT1FLT3FLT4GARTGHSRGRIA1GRIA2GRIA3GRIA4GRIK1GRIK2GRIK3GRIK4GRIK5GRIN2AGSK3AGSK3BHDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IDH1IDH2IMPA1ITGA2BITGB3JAK1JAK2JAK3KCNJ11KCNK3KCNK9KDRKITMEN1METMMP1MMP13MMP7MMP8NANOD2NS5bODC1OPG057OPRD1OPRK1OPRM1PPARP1PARP2PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PKLRPPARDPPATPTGS1PTGS2RBX1ROCK1ROCK2RRM1RRM2RRM2BSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC10A2SLC5A2SLC6A2SLC6A3SLC6A4SLC9A3SYKTACR1THRATHRBTOP1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYK2TYMSVDRampCblablaT-3blaT-4blaT-5blaT-6blaUOE-1dacAdacBdacCfolAfolPftsIgyrAgyrBileSmecAmrcAmrcBmrdAparCparEpbp2pbp4pbpApbpFrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUthyAykgMykgO
The experimentally established mechanism targets of Water. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKLR known ✓ | P30613 | 4/20 | 0.60 |
| ▸ | MEN1 known ✓ | O00255 | 2/20 | 0.54 |
| ▸ | PARG | Q86W56 | 7/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.49 |
| ▸ | STAT3 | P40763 | 1/20 | 0.49 |
| ▸ | ELANE | P08246 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CDC25B | P30305 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL30203790 | 1.00 | PKLR (0.60) | PKLRPARGSMN1; SMN2KMT2AMAPK1 | |
| SCHEMBL305527 | 0.98 | PKLR (0.62) | PKLRPARGSMN1; SMN2KMT2AMAPK1 | |
| SCHEMBL28367628 | 0.98 | PKLR (0.62) | PKLRPARGSMN1; SMN2KMT2AMAPK1 | |
| SCHEMBL32662068 | 0.98 | PKLR (0.62) | PKLRPARGSMN1; SMN2KMT2AMAPK1 | |
| SCHEMBL29384291 | 0.98 | PKLR (0.62) | PKLRPARGSMN1; SMN2KMT2AMAPK1 | |
| SCHEMBL2858677 | 0.94 | PARG (0.59) | PKLRPARGSMN1; SMN2KMT2AMAPK1 | |
| Potassium Ion SCHEMBL2784885 | 0.94 | PARG (0.59) | PKLRPARGSMN1; SMN2KMT2AMAPK1 | |
| SCHEMBL8985955 | 0.94 | PARG (0.59) | PKLRPARGSMN1; SMN2KMT2AMAPK1 | |
| SCHEMBL9235321 | 0.94 | PARG (0.59) | PKLRPARGSMN1; SMN2KMT2AMAPK1 | |
| Silver SCHEMBL11327330 | 0.94 | PARG (0.59) | PKLRPARGSMN1; SMN2KMT2AMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119447273-B | Lithium ion battery positive electrode material, preparation method thereof and lithium ion battery | 赣州诺威科技有限公司 | 2025-04-29 | — | — | CN | claimed |
| US-20250073673-A1 | NANONETS FOR REMOVAL OF CONTAMINANTS FROM AQUEOUS SOLUTIONS, KITS THEREFOR AND METHODS OF THEIR USE | CARBONET NANOTECHNOLOGIES INC. (CA) | 2025-03-06 | — | — | US | claimed |
| CN-119447273-A | Lithium ion battery positive electrode material, preparation method thereof and lithium ion battery | 赣州诺威科技有限公司 | 2025-02-14 | — | — | CN | claimed |
| EP-4414063-A1 | NANONETS FOR REMOVAL OF CONTAMINANTS FROM AQUEOUS SOLUTIONS, KITS THEREFOR AND METHODS OF THEIR USE | Carbonet Nanotechnologies Inc. (CA) | 2024-08-14 | — | — | EP | claimed |
| US-20240168374-A1 | PHOTORESIST COMPOSITION | TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY, LTD. (TW) | 2024-05-23 | — | — | US | claimed |
| CN-111977621-B | Production method of light-driven high-purity nitrous oxide | 福建农林大学 | 2022-10-14 | — | — | CN | claimed |
| US-12624174-B2 | Hydrogen-bond enriched ion exchange membranes | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2026-05-12 | — | — | US | disclosed |
| EP-4414063-B1 | NANONETS FOR REMOVAL OF CONTAMINANTS FROM AQUEOUS SOLUTIONS, KITS THEREFOR AND METHODS OF THEIR USE | CARBONET NANOTECHNOLOGIES INC (CA) | 2026-04-15 | — | — | EP | disclosed |
| EP-4721721-A1 | CURABLE COMPOSITION COMPRISING AN ALKOXYLATED ISOSORBIDE DI(METH)ACRYLATE | ARKEMA FRANCE (FR) | 2026-04-08 | — | — | EP | disclosed |
| EP-4723180-A1 | CURABLE COMPOSITIONS FOR THE MANUFACTURE OF ELECTRODES OF LITHIUM ION BATTERIES | ARKEMA FRANCE (FR) | 2026-04-08 | — | — | EP | disclosed |
| EP-4717744-A1 | USE OF A COMPOSITION BASED ON CYANOACRYLATE AND (METH)ACRYLATE | Bostik SA (FR) | 2026-04-01 | — | — | EP | disclosed |
| EP-4711042-A1 | TARGET OBJECT SEPARATION APPARATUS WITH IMPROVED QUALITY CONTROL, AND MANUFACTURING METHOD THEREOF | CURIOSIS INC. (KR) | 2026-03-18 | — | — | EP | disclosed |
| US-12540247-B2 | Primer composition | THREEBOND CO., LTD. (JP) | 2026-02-03 | — | — | US | disclosed |
| US-7291427-B2 | Surface graft material, conductive pattern material, and production method thereof | FUJIFILM CORPORATION (JP) | 2007-11-06 | — | — | US | disclosed |
| US-20050214550-A1 | Method of forming a pattern, conductive patterned material, and method of forming a conductive pattern | FUJI PHOTO FILM CO., LTD. | 2005-09-29 | — | — | US | disclosed |
| EP-1581031-A1 | Method of forming a pattern, conductive patterned material, and method of forming a conductive pattern | Fuji Photo Film Co. Ltd. (JP) | 2005-09-28 | — | — | EP | disclosed |
| US-20050208428-A1 | Surface graft material, conductive pattern material, and production method thereof | FUJI PHOTO FILM CO., LTD. | 2005-09-22 | — | — | US | disclosed |
| US-6811878-B2 | MULTILAYER; RADIATION TRANSPARENT SUPPORT, CONDUCTIVE PARTICLES | FUJI PHOTO FILM CO., LTD. (JP) | 2004-11-02 | — | — | US | disclosed |
| US-20030008135-A1 | Conductive film | FUJIFILM CORPORATION (JP) | 2003-01-09 | — | — | US | disclosed |
| EP-1271561-A2 | Conductive film | FUJI PHOTO FILM CO., LTD. (JP) | 2003-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12540247-B2 | Primer composition | FGB, CDH1, F10 | PKLR 3239/4885MEN1 4605/4885PARG 674/4885 |
| US-12624174-B2 | Hydrogen-bond enriched ion exchange membranes | SLC9A2, SLC9A3, SLC9A1 | PKLR 1639/4885MEN1 671/4885PARG 349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.